Protecting Your Patients with Type 2 Diabetes
The introduction of newer antihyperglycemic agents, including GLP-1 RAs and SGLT2 inhibitors, has increasingly expanded the opportunities for improving clinical outcomes in patients with type 2 diabetes.1
This program supports primary care physicians in navigating the changing diabetes landscape beyond glycemic control.
The efficacy and clinical evidence of antihyperglycemic agents in lowering blood glucose and providing cardiovascular protection will be illustrated through case-based learning, with the goal of increasing clinicians’ confidence in adjusting or advancing therapy according to the most recent recommendations from Diabetes Canada.
This program has been developed in collaboration with M3 (EU) Ltd.
This program has received an education grant or in-kind support from Novo Nordisk.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits. Cert+ Program ID#: 193553
Daniel Ngui, MD, CCFP, FCFP
Jane Ballantine, MD
Jeffrey Habert, MD, CCFP, FCFP
Ronald Goldenberg, MD, FRCPC, FACE
Upon completion of this continuing education program, participants will be better able to:
- Help patients reach glycemic targets within 3-6 months of diagnosis to avoid complications of type 2 diabetes
- Apply Diabetes Canada guideline recommendations into practice to ensure effective management of type 2 diabetes
- Implement treatment plans to optimize cardiovascular protection of patients with type 2 diabetes, when indicated